Lung Disease Breakthrough Boosts United Therapeutics — and Its Rivals

Lung Disease Breakthrough Boosts United Therapeutics — and its Rivals

United Therapeutics shares rose a breathtaking 33% on Tuesday — actually, it might be more appropriate to say they rose a breath-giving 33%. The biotech company announced the results of a late-stage study showing its drug Tyvaso significantly enhanced lung function in people with a rare, progressive lung disease. A multi-billion dollar market opportunity is in the wings, and the news was enough to lift United Therapeutics’ rivals pursuing simila…

Tyvaso boosts lung function in IPF trial, per top-line data

Tyvaso significantly improved a measure of lung function for IPF patients in a Phase 3 trial, which top-line data showed met its main goal.

United’s Tyvaso scores in Phase III IPF trial

If approved, United's Tyvaso could redefine SoC for idiopathic pulmonary fibrosis (IPF), a GlobalData analyst tells Clinical Trials Arena.The post United’s Tyvaso scores in Phase III IPF trial appeared first on Clinical Trials Arena.

United's lung disease drug Tyvaso succeeds in Phase 3 IPF trial

United Therapeutics’ stock price soared Tuesday after the company reported a Phase 3 win in a lung disease that’s had a spate of failures. Tyvaso hit the primary goal in the ...